Normal Saline Infusion for Stroke After Intravenous Thrombolysis

• Status: Recruiting
• Trial end date: 2025-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to explore the safety and efficacy of 0.9% normal saline （NS） infusion on stroke after intravenous thrombolysis (IVT), we decided to conduct this multi-centre randomized controlled trial for the first time. This trial will provide an innovative strategy to facilitate functional independence after stroke administered with IVT. This is a multi-center, randomized controlled two arm (1:1 ratio) clinical trial. The enrolled participators will be divided into NS group and control group randomly after confirming as acute ischemic stroke (AIS) according to symptoms and signs. In NS group, the patient will undergo NS 2000ml intravenous infusion swiftly after IVT, with the speed of 200ml/h. In control group, the patient will not undergo NS intravenous infusion after IVT. The primary efficacy is disability at days 90, as scored by means of the modified Rankin scale (mRS), dichotomized as a favorable outcome (a score of 0 or 1), or an unfavorable outcome (a score of 2 to 6). The secondary outcomes mainly comprise neurological deficits, disability, imaging and laboratory tests at each follow-up time. The safety outcomes include the cerebral edema at 24-hour post-IVT detected by cranial CT, the 24-hour fluctuation of blood pressure and the cardiac function detected by ultrasonic cardiogram within 3 days after IVT. Stata 15.1 and R software will be used for statistical analysis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin Medical University General Hospital

Criteria

Inclusion Criteria：

• Acute ischemic stroke (AIS)

• Age 18-80 years

• Pre-stroke mRS≤1

• Onset-to-needle time≤4.5 hours

• Treated with alteplase

• Initial diagnosis of penetrating artery disease, large artery atherosclerosis (LAA) inducing parent artery (plaque or thrombus) occluding penetrating artery and LAA inducing hypoperfusion defined by Chinese ischemic stroke subclassification (CISS) system

• Sign the informed consent

Exclusion Criteria：

• Severe AIS, including NIHSS score>20 in dominant hemisphere infarction, or NIHSS score>15 in non-dominant hemisphere infarction, or NIHSS consciousness score >1

• Massive infarction, characterized by infarction area larger than 1/3 of the effected middle cerebral artery (MCA) territory and/or the cerebellum territory presented in admitted CT or MRI

• Initial diagnosis of LAA inducing artery-to-artery embolism, cardiogenic stroke, other etiologies and undetermined etiologies defined by CISS system

• Intention to undergo endovascular treatment

• Intention to undergo antiplatelet drugs within 24 hours after IVT, such as aspirin, clopidogrel, ticagrelor, cilostazol and tirofiban

• Allergy to alteplase

• Arterial puncture at a non-compressible site within previous 7 days, major surgery within previous 14 days, sever trauma, gastrointestinal or urinary tract bleeding within previous 21 days

• Cerebral infarction or myocardial infarction within previous 3 months, previous intracranial haemorrhage (ICH) including parenchymal haemorrhage, intraventricular haemorrhage, subarachnoid haemorrhage, subdural/external haematoma, etc

• Severe brain trauma, intracranial or intraspinal surgery within previous 3 months or known malignant intracranial neoplasm, giant intracranial aneurysm or arteriovenous malformation

• Persistent systolic blood pressure≥180mmHg or diastolic blood pressure≥100mmHg

• Admitted blood glucose<2.8mmol/L or >22.22mmol/L

• Defect in coagulation, for example, current use of oral warfarin with an international normalised ratio>1.7, or prothrombin time>15s, or heparins during the last 48 hours, or use of direct thrombin inhibitors or direct factor Xa inhibitors during the last 48 hours or with an elevated activated partial thromboplastin time

• Platelet count<100×109/L

• Stroke mimics, such as seizure and hysteria

• Brain haemorrhage identified by CT or MRI

• Any terminal illness such that patients would not be expected to survive>1 year

• Pregnant women or nursing mother

• Poor compliance

• Participating in other clinical trials within previous 3 months.